Related Experiment Video
Updated: Aug 6, 2025

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Osteosarcoma-enriched transcripts paradoxically generate osteosarcoma-suppressing extracellular proteins
Kexin Li1,2, Qingji Huo1,2, Nathan H Dimmitt2
1Department of Pharmacology, School of Pharmacy, Harbin Medical University, Harbin, China.
Abstract:
Osteosarcoma (OS) is the common primary bone cancer that affects mostly children and young adults. To augment the standard-of-care chemotherapy, we examined the possibility of protein-based therapy using mesenchymal stem cells (MSCs)-derived proteomes and OS-elevated proteins. While a conditioned medium (CM), collected from MSCs, did not present tumor-suppressing ability, the activation of PKA converted MSCs into induced tumor-suppressing cells (iTSCs). In a mouse model, the direct and hydrogel-assisted administration of CM inhibited tumor-induced bone destruction, and its effect was additive with cisplatin. CM was enriched with proteins such as calreticulin, which acted as an extracellular tumor suppressor by interacting with CD47. Notably, the level of CALR transcripts was elevated in OS tissues, together with other tumor-suppressing proteins, including histone H4, and PCOLCE. PCOLCE acted as an extracellular tumor-suppressing protein by interacting with amyloid precursor protein, a prognostic OS marker with poor survival. The results supported the possibility of employing a paradoxical strategy of utilizing OS transcriptomes for the treatment of OS.
Insights
Mesenchymal stem cell-derived proteins show potential in treating osteosarcoma (OS) by inhibiting bone destruction. Activating specific pathways in stem cells enhanced their tumor-suppressing capabilities, offering a novel therapeutic avenue for this bone cancer.
Area of Science:
- Oncology
- Biotechnology
- Regenerative Medicine
Background:
- Osteosarcoma (OS) is a primary bone cancer predominantly affecting children and young adults.
- Standard chemotherapy for OS has limitations, necessitating novel therapeutic strategies.
- Mesenchymal stem cells (MSCs) and their secreted proteins are being explored for cancer therapy.
Purpose of the Study:
- To investigate the potential of MSCs-derived proteomes and OS-elevated proteins as a protein-based therapy for osteosarcoma.
- To evaluate the tumor-suppressing ability of MSCs-conditioned medium (CM) and modified MSCs (iTSCs).
- To explore the therapeutic efficacy of CM in inhibiting tumor-induced bone destruction in a mouse model.
Main Methods:
- Collected conditioned medium (CM) from MSCs and activated MSCs (iTSCs) via PKA activation.
- Administered CM directly and via hydrogel in a mouse model of OS.
- Analyzed protein enrichment in CM, including calreticulin (CALR) and PCOLCE.
- Examined interactions between identified proteins (e.g., CALR with CD47, PCOLCE with amyloid precursor protein) and their expression in OS tissues.
Main Results:
- MSCs-derived CM inhibited tumor-induced bone destruction in a mouse model, with additive effects when combined with cisplatin.
- Activation of PKA converted MSCs into induced tumor-suppressing cells (iTSCs).
- Calreticulin (CALR) and PCOLCE were identified as extracellular tumor suppressors in CM, with elevated CALR transcripts in OS tissues.
- PCOLCE interacted with amyloid precursor protein, a poor prognostic marker in OS.
Conclusions:
- MSCs-derived proteins, particularly calreticulin and PCOLCE, demonstrate extracellular tumor-suppressing activity against osteosarcoma.
- A paradoxical strategy utilizing OS transcriptomes for treatment, potentially through engineered MSCs, is supported by these findings.
- This study highlights the potential of protein-based therapies derived from stem cells and leveraging tumor-specific proteins for osteosarcoma treatment.
More Related Videos
11:15A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
04:25Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Abnormal Proliferation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...